

Karin Neukam

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9036290/publications.pdf>

Version: 2024-02-01

85
papers

1,589
citations

331259

21
h-index

344852

36
g-index

87
all docs

87
docs citations

87
times ranked

2231
citing authors

#	ARTICLE	IF	CITATIONS
1	Long-Term Ingestion of High Flavanol Cocoa Provides Photoprotection against UV-Induced Erythema and Improves Skin Condition in Women. <i>Journal of Nutrition</i> , 2006, 136, 1565-1569.	1.3	148
2	Prediction of Response to Pegylated Interferon plus Ribavirin by IL28B Gene Variation in Patients Coinfected with HIV and Hepatitis C Virus. <i>Clinical Infectious Diseases</i> , 2010, 51, 788-795.	2.9	140
3	Chronic Hepatitis E in HIV Patients: Rapid Progression to Cirrhosis and Response to Oral Ribavirin. <i>Clinical Infectious Diseases</i> , 2013, 57, 465-468.	2.9	96
4	Consumption of flavanol-rich cocoa acutely increases microcirculation in human skin. <i>European Journal of Nutrition</i> , 2007, 46, 53-56.	1.8	94
5	Epidemiology of anal human papillomavirus infection and high-grade squamous intraepithelial lesions in 29,900 men according to HIV status, sexuality, and age: a collaborative pooled analysis of 64 studies. <i>Lancet HIV</i> , 2021, 8, e531-e543.	2.1	77
6	Modeling the Probability of Sustained Virological Response to Therapy with Pegylated Interferon plus Ribavirin in Patients Coinfected with Hepatitis C Virus and HIV. <i>Clinical Infectious Diseases</i> , 2010, 51, 1209-1216.	2.9	56
7	Influence of Interleukin-28B Single-Nucleotide Polymorphisms on Progression to Liver Cirrhosis in Human Immunodeficiency Virus/Hepatitis C Virus Coinfected Patients Receiving Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2011, 203, 1629-1636.	1.9	55
8	Supplementation of Flaxseed Oil Diminishes Skin Sensitivity and Improves Skin Barrier Function and Condition. <i>Skin Pharmacology and Physiology</i> , 2011, 24, 67-74.	1.1	52
9	Hepatitis C virus reinfection after sustained virological response in HIV-infected patients with chronic hepatitis C. <i>Journal of Infection</i> , 2015, 71, 571-577.	1.7	42
10	Low-density lipoprotein receptor genotyping enhances the predictive value of IL28B genotype in HIV/hepatitis C virus-coinfected patients. <i>Aids</i> , 2011, 25, 1415-1420.	1.0	40
11	Prediction of response to pegylated interferon plus ribavirin in HIV/hepatitis C virus (HCV)-coinfected patients using HCV genotype, IL28B variations, and HCV-RNA load. <i>Journal of Hepatology</i> , 2012, 56, 788-794.	1.8	34
12	Interobserver concordance in controlled attenuation parameter measurement, a novel tool for the assessment of hepatic steatosis on the basis of transient elastography. <i>European Journal of Gastroenterology and Hepatology</i> , 2013, 25, 905-911.	0.8	32
13	HIV-coinfected patients respond worse to direct-acting antiviral-based therapy against chronic hepatitis C in real life than HCV-monoinfected individuals: a prospective cohort study. <i>HIV Clinical Trials</i> , 2017, 18, 126-134.	2.0	31
14	Tea flavanols inhibit cell growth and DNA topoisomerase II activity and induce endoreduplication in cultured Chinese hamster cells. <i>Mutation Research - Genetic Toxicology and Environmental Mutagenesis</i> , 2008, 654, 8-12.	0.9	29
15	Changes in liver stiffness in patients with chronic hepatitis C with and without HIV co-infection treated with pegylated interferon plus ribavirin. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 2204-2211.	1.3	29
16	Interobserver concordance in the assessment of liver fibrosis in HIV/HCV-coinfected patients using transient elastometry. <i>European Journal of Gastroenterology and Hepatology</i> , 2010, 22, 801-807.	0.8	26
17	Liver toxicity associated with antiretroviral therapy including efavirenz or ritonavir-boosted protease inhibitors in a cohort of HIV/hepatitis C virus co-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 2605-2614.	1.3	26
18	IFNL4 rs469415590 Variant Shows Similar Performance to rs12979860 as Predictor of Response to Treatment against Hepatitis C Virus Genotype 1 or 4 in Caucasians. <i>PLoS ONE</i> , 2014, 9, e95515.	1.1	24

#	ARTICLE	IF	CITATIONS
19	Reassessment of Genotype 1 Hepatitis C Virus Subtype Misclassification by LiPA 2.0: Implications for Direct-Acting Antiviral Treatment. <i>Journal of Clinical Microbiology</i> , 2014, 52, 4027-4029.	1.8	23
20	Changes in liver steatosis evaluated by transient elastography with the controlled attenuation parameter in HIV-infected patients. <i>HIV Medicine</i> , 2016, 17, 766-773.	1.0	23
21	A review of current anti-HCV treatment regimens and possible future strategies. <i>Expert Opinion on Pharmacotherapy</i> , 2009, 10, 417-433.	0.9	22
22	Liver Toxicity of Initial Antiretroviral Drug Regimens Including Two Nucleoside Analogs Plus One Non-Nucleoside Analog or One Ritonavir-Boosted Protease Inhibitor in HIV/HCV-Coinfected Patients. <i>HIV Clinical Trials</i> , 2012, 13, 61-69.	2.0	21
23	Impact of IL28B polymorphisms on response to peginterferon and ribavirin in HIV-hepatitis C virus-coinfected patients with prior nonresponse or relapse. <i>Aids</i> , 2011, 25, 1131-1133.	1.0	20
24	Liver tolerance of raltegravir-containing antiretroviral therapy in HIV-infected patients with chronic hepatitis C. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 1346-1350.	1.3	19
25	Impact of genetic polymorphisms associated with nonalcoholic fatty liver disease on HIV-infected individuals. <i>Aids</i> , 2015, 29, 1927-1935.	1.0	19
26	Association between the IL28B genotype and hepatitis C viral kinetics in the early days of treatment with pegylated interferon plus ribavirin in HIV/HCV co-infected patients with genotype 1 or 4. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 202-205.	1.3	17
27	Combined use of aspartate aminotransferase, platelet count and matrix metalloproteinase 2 measurements to predict liver fibrosis in HIV/hepatitis C virus-coinfected patients. <i>HIV Medicine</i> , 2011, 12, 14-21.	1.0	16
28	Different distributions of hepatitis C virus genotypes among HIV-infected patients with acute and chronic hepatitis C according to interleukin-28B genotype. <i>HIV Medicine</i> , 2011, 12, 487-493.	1.0	16
29	Association of low-density lipoprotein receptor genotypes with hepatitis C viral load. <i>Genes and Immunity</i> , 2014, 15, 16-24.	2.2	16
30	The impact of interleukin 28B rs12979860 single nucleotide polymorphism and liver fibrosis stage on response-guided therapy in HIV/HCV-coinfected patients. <i>Aids</i> , 2013, 27, 2707-2714.	1.0	15
31	Impact of interferon-free regimens on the glomerular filtration rate during treatment of chronic hepatitis C in a real-life cohort. <i>Journal of Viral Hepatitis</i> , 2018, 25, 699-706.	1.0	15
32	Differences in Virological Response to Peginterferon- α Plus Ribavirin in HIV-Positive Patients Coinfected With HCV Subtypes 1a or 1b. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, 60, 117-123.	0.9	12
33	LDLr genotype modifies the impact of IL28B on HCV viral kinetics after the first weeks of treatment with PEG-IFN/RBV in HIV/HCV patients. <i>Aids</i> , 2012, 26, 1009-1015.	1.0	12
34	Boceprevir or Telaprevir Based Triple Therapy against Chronic Hepatitis C in HIV Coinfection: Real-Life Safety and Efficacy. <i>PLoS ONE</i> , 2015, 10, e0125080.	1.1	12
35	Liver Toxicity of Current Antiretroviral Regimens in HIV-Infected Patients with Chronic Viral Hepatitis in a Real-Life Setting: The HEPAVIR SEG-HEP Cohort. <i>PLoS ONE</i> , 2016, 11, e0148104.	1.1	12
36	Sustained virological response to pegylated interferon plus ribavirin leads to normalization of liver stiffness in hepatitis C virus-infected patients. <i>Enfermedades Infecciosas Y Microbiologa Clnica</i> , 2013, 31, 424-429.	0.3	11

#	ARTICLE	IF	CITATIONS
37	High frequency of potential interactions between direct-acting antivirals and concomitant therapy in HIV/hepatitis C virus-coinfected patients in clinical practice. <i>HIV Medicine</i> , 2017, 18, 445-451.	1.0	11
38	Twelve week post-treatment follow-up predicts sustained virological response to pegylated interferon and ribavirin therapy in HIV/hepatitis C virus co-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 1351-1353.	1.3	10
39	Hepatic safety of efavirenz in HIV/hepatitis C virus-coinfected patients with advanced liver fibrosis. <i>Journal of Infection</i> , 2012, 64, 204-211.	1.7	10
40	Effects of the genetic pattern defined by low-density lipoprotein receptor and IL28B genotypes on the outcome of hepatitis C virus infection. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2013, 32, 1427-1435.	1.3	10
41	Pegylated interferon plus ribavirin is suboptimal in IL28B CC carriers without rapid response. <i>Journal of Infection</i> , 2013, 67, 59-64.	1.7	10
42	Hepatitis C virus genotype 1 infection: Prevalence of NS5A and NS5B resistance-associated substitutions in HIV-1 patients from Argentina. <i>Journal of Medical Virology</i> , 2019, 91, 1970-1978.	2.5	10
43	A polymorphism linked to <i>RRAS</i> , <i>SCAF1</i> , <i>IRF3</i> and <i>BCL2L12</i> genes is associated with cirrhosis in hepatitis C virus carriers. <i>Liver International</i> , 2014, 34, 558-566.	1.9	9
44	High-resolution anoscopy in HIV-infected men: Assessment of the learning curve and factors that improve the performance. <i>Papillomavirus Research (Amsterdam, Netherlands)</i> , 2019, 7, 62-66.	4.5	9
45	High-risk Human Papilloma Virus Testing Improves Diagnostic Performance to Predict Moderate- to High-grade Anal Intraepithelial Neoplasia in Human Immunodeficiency Virus-infected Men Who Have Sex With Men in Low-to-Absent Cytological Abnormalities. <i>Clinical Infectious Diseases</i> , 2019, 69, 2185-2192.	2.9	9
46	Incidence Rate and Risk Factors for Anal Squamous Cell Carcinoma in a Cohort of People Living With HIV from 2004 to 2017: Implementation of a Screening Program. <i>Diseases of the Colon and Rectum</i> , 2022, 65, 28-39.	0.7	9
47	HAART and the liver: friend or foe?. <i>European Journal of Medical Research</i> , 2010, 15, 93.	0.9	8
48	HIV-coinfection leads to a modest increase in plasma HCV-RNA load in patients with chronic HCV infection. <i>Antiviral Research</i> , 2012, 95, 212-215.	1.9	8
49	Hepatitis C virus genotype 4 in Southern and Central Spain does not originate from recent foreign migration waves. <i>Journal of Medical Virology</i> , 2013, 85, 1734-1740.	2.5	8
50	Impact of HIV infection on sustained virological response to treatment against hepatitis C virus with pegylated interferon plus ribavirin. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2015, 34, 1929-1936.	1.3	8
51	Week 4 response predicts sustained virological response to all-oral direct-acting antiviral-based therapy in cirrhotic patients with hepatitis C virus genotype 3 infection. <i>Clinical Microbiology and Infection</i> , 2017, 23, 409.e5-409.e8.	2.8	8
52	Brief Report: Response to Hepatitis A Virus Vaccine in HIV-Infected Patients Within a Retrospective, Multicentric Cohort: Facing Hepatitis A Outbreaks in the Clinical Practice. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 81, e1-e5.	0.9	8
53	Hepatic Safety of Rilpivirine/Emtricitabine/Tenofovir Disoproxil Fumarate Fixed-Dose Single-Tablet Regimen in HIV-Infected Patients with Active Hepatitis C Virus Infection: The hEPAtic Study. <i>PLoS ONE</i> , 2016, 11, e0155842.	1.1	8
54	Variations at multiple genes improve interleukin 28B genotype predictive capacity for response to therapy against hepatitis C infection. <i>Aids</i> , 2013, 27, 2715-2724.	1.0	7

#	ARTICLE	IF	CITATIONS
55	Efficacy of chronic hepatitis C therapy with pegylated interferon and ribavirin in patients on methadone maintenance treatment. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2012, 31, 1225-1232.	1.3	6
56	Baseline risk factors for relapse in HIV/HCV co-infected patients treated with PEG-IFN/RBV. <i>Infection</i> , 2013, 41, 21-26.	2.3	6
57	Latest pharmacotherapy options for treating hepatitis C in HIV-infected patients. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 1837-1848.	0.9	6
58	Fat mass and obesity-associated gene variations are related to fatty liver disease in HIV-infected patients. <i>HIV Medicine</i> , 2017, 18, 546-554.	1.0	6
59	Response to a reinforced hepatitis B vaccination scheme in HIV-infected patients under real-life conditions. <i>Vaccine</i> , 2019, 37, 2758-2763.	1.7	6
60	Strategies for Assignment of HIV-HCV Genotype-1-Coinfected Patients to Either Dual-Therapy or Direct-Acting Antiviral Agent-Based Triple-Therapy. <i>Antiviral Therapy</i> , 2014, 19, 407-414.	0.6	5
61	Dimension of chronic hepatitis C virus in HIV-infected patients in the interferon-free era: an overview from south Spain. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2015, 34, 2247-2255.	1.3	5
62	No evidence of firstly acquired acute hepatitis C virus infection outbreak among HIV-infected patients from Southern Spain: a multicentric retrospective study from 2000-2014. <i>BMC Infectious Diseases</i> , 2016, 16, 489.	1.3	5
63	Prevalence of hepatitis C virus infection according to the year of birth: identification of risk groups. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2018, 37, 247-254.	1.3	5
64	A model to predict the response to therapy against hepatitis C virus (HCV) including low-density lipoprotein receptor genotype in HIV/HCV-coinfected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 915-921.	1.3	4
65	Liver stiffness predicts the response to direct-acting antiviral-based therapy against chronic hepatitis C in cirrhotic patients. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2017, 36, 853-861.	1.3	4
66	NS3 genomic sequencing and phylogenetic analysis as alternative to a commercially available assay to reliably determine hepatitis C virus subtypes 1a and 1b. <i>PLoS ONE</i> , 2017, 12, e0182193.	1.1	4
67	Core amino acid variation at position 110 is associated with sustained virological response in Caucasian patients with chronic hepatitis C virus 1b infection. <i>Archives of Virology</i> , 2014, 159, 3345-3351.	0.9	3
68	Sustained virological response in HIV/HCV co-infected patients treated with pegylated interferon/ribavirin can be predicted from the overall rate of viral load decline over the first 4 weeks of therapy. <i>Journal of Infection</i> , 2014, 68, 372-377.	1.7	3
69	HIV Coinfection Impairs Response to DAA-Based HCV Therapy. <i>Journal of Hepatology</i> , 2016, 64, S219.	1.8	3
70	Efficacy of and risk of bleeding during pegylated interferon plus ribavirin treatment in HIV/HCV-coinfected patients with pretreatment thrombocytopenia. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2015, 34, 1879-1884.	1.3	2
71	Short-term effect of DAA IFN-free regimens on liver stiffness. <i>Journal of Hepatology</i> , 2017, 66, S525.	1.8	2
72	Impact of Observer Experience on the Reproducibility of Transient Elastometry in HIV/HCV Co-infected Patients. <i>HIV Clinical Trials</i> , 2009, 10, 276-281.	2.0	1

#	ARTICLE	IF	CITATIONS
73	Liver safety of two nucleoside analogs plus efavirenz, nevirapine or a ritonavir-boosted protease inhibitor in HIV/HCV-coinfected drug-naïve patients. <i>Journal of the International AIDS Society</i> , 2010, 13, P91-P91.	1.2	1
74	882 GENETIC VARIATIONS IN proprotein convertase subtilisin/kexin type 9 (PCSK9) GENE ARE ASSOCIATED WITH RESPONSE TO PEGYLATED INTERFERON/RIBAVIRIN IN HEPATITIS C VIRUS GENOTYPE 3-INFECTED PATIENTS. <i>Journal of Hepatology</i> , 2013, 58, S362.	1.8	1
75	1352 INTEROBSERVER CONCORDANCE IN CONTROLLED ATTENUATION PARAMETER (CAP) MEASUREMENT, A NOVEL TOOL FOR THE ASSESSMENT OF HEPATIC STEATOSIS BASED ON TRANSIENT ELASTOGRAPHY. <i>Journal of Hepatology</i> , 2013, 58, S544.	1.8	1
76	Changes in the response to treatment against chronic hepatitis C between 1999 and 2015. <i>European Journal of Gastroenterology and Hepatology</i> , 2016, 28, 1253-1257.	0.8	1
77	Low incidence of acute hepatitis C virus infection among Southern Spanish HIV-infected individuals. <i>Journal of Infection</i> , 2017, 74, 514-517.	1.7	1
78	Sustained virological response in HIV/HCV co-infected patients without rapid virological response (RVR) on peginterferon-ribavirin therapy. <i>Journal of the International AIDS Society</i> , 2010, 13, P208-P208.	1.2	0
79	1173 VARIATION IN INTERLEUKIN 28B GEN PREDICTS RESPONSE TO PEGYLATED INTERFERON PLUS RIBAVIRIN IN HIV/HEPATITIS C VIRUS-COINFECTED PATIENTS. <i>Journal of Hepatology</i> , 2010, 52, S453.	1.8	0
80	Influence of the Combination of Low-Density Lipoprotein Receptor and Interleukin 28B Genotypes on Lipid Plasma Levels in HIV/Hepatitis C-Coinfected Patients. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2011, 58, e115-e117.	0.9	0
81	883 PREDICTION OF RESPONSE TO PEGYLATED INTERFERON/RIBAVIRIN BY INTERLEUKIN 28B GENOTYPE IS MODIFIED BY SNPS AT MULTIPLE GENES IN HIV/HEPATITIS C VIRUS GENOTYPE 1/4-COINFECTED PATIENTS. <i>Journal of Hepatology</i> , 2013, 58, S363.	1.8	0
82	489 AN ALLELIC VARIANT IN THE IRF3 GENE IS ASSOCIATED WITH LIVER CIRRHOSIS IN HEPATITIS C VIRUS CARRIERS. <i>Journal of Hepatology</i> , 2013, 58, S200.	1.8	0
83	Hepatic safety of RPV/FTC/TDF single tablet regimen in HIV/HCV-coinfected patients. Preliminary results of the hEPatic Study. <i>Journal of the International AIDS Society</i> , 2014, 17, 19631.	1.2	0
84	Impact of IL28B Genotype on First-Week Response to Telaprevir-Based Therapy in HIV-HCV Coinfection. <i>Antiviral Therapy</i> , 2015, 20, 407-413.	0.6	0
85	Efficacy of therapy against chronic hepatitis C virus genotype 1 infection in HIV-coinfected patients with several interferon-free DAA combinations: real life data from the HEPAVIR-DAA Cohort. <i>Journal of Hepatology</i> , 2017, 66, S526-S527.	1.8	0